Elgenedi, H., Abdelhalim, I., Eita, M., Elshahat, M., Arafa, M. (2020). Predictive and Prognostic Relevance of p53 in Patients With Serous Epithelial Ovarian Cancer. test, 37(1), 184-192. doi: 10.21608/bmfj.2020.77406
Hind Abdelhamid Elgenedi; Inas Abdelhalim; Mahfouz Eita; Maiy Elshahat; Mohammed Arafa. "Predictive and Prognostic Relevance of p53 in Patients With Serous Epithelial Ovarian Cancer". test, 37, 1, 2020, 184-192. doi: 10.21608/bmfj.2020.77406
Elgenedi, H., Abdelhalim, I., Eita, M., Elshahat, M., Arafa, M. (2020). 'Predictive and Prognostic Relevance of p53 in Patients With Serous Epithelial Ovarian Cancer', test, 37(1), pp. 184-192. doi: 10.21608/bmfj.2020.77406
Elgenedi, H., Abdelhalim, I., Eita, M., Elshahat, M., Arafa, M. Predictive and Prognostic Relevance of p53 in Patients With Serous Epithelial Ovarian Cancer. test, 2020; 37(1): 184-192. doi: 10.21608/bmfj.2020.77406

Predictive and Prognostic Relevance of p53 in Patients With Serous Epithelial Ovarian Cancer

Benha Medical Journal
Article 4, Volume 37, Issue 1, May 2020, Pages 184-192    PDF (826.13 K)
Document Type: Original Article
DOI: 10.21608/bmfj.2020.77406
Authors
Hind Abdelhamid Elgenedi* 1; Inas Abdelhalim2; Mahfouz Eita2; Maiy Elshahat2; Mohammed Arafa3
1Clinical oncology, Mansoura university, Dakahleyia, Egypt
2Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Mansoura University Egypt
3department of Pathology, Faculty of Medicine, Mansoura University, Egypt
Abstract
Background:  Ovarian cancer is a common malignant gynecological tumor that is difficult to diagnose early, progresses rapidly, and causes high mortality. Aims of our study: to assess the relationship of P53 with other clinico-pathological parameters and the effect of P53 on patients’ out-come.
Subjects and methods: This study was conducted at Clinical Oncology and Nuclear Medicine Department  with Pathology Department, Faculty of Medicine, Mansoura University. The study was carried out on 50 patients with serous epithelial ovarian cancer presented to receive adjuvant treatments following a primary surgery and were followed from the first day after surgery, follow-up started on January, 2012 till February, 2016. P53 expression was assessed immunohistochemically on formalin-fixed paraffin-embedded tissues, and Secondary red Envision system. Patients were given adjuvant treatment(s) according to according to NCCN guidelines. The primary endpoint of the study was loco regional recurrence, and distant metastasis. At the end of the follow-up period, the patient clinico-pathological data and patient outcome were collected.
Results: we found that p53 negative tumors  have a better OS & DFS at 3 year than with P53 positive tumors, but not reached statistically significant differences ( p value = 0.98 & 0.48 respectively).
Conclusion: Our results showed no statically significant difference between p53 expression. OS & DFS, need to be evaluated in other study including large number of patients before using it as a marker for the outcome in these tumors.
Statistics
Article View: 176
PDF Download: 496